Results 31 to 40 of about 37,133 (255)

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]

, 2017
An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant ...
Chmielowski, Bartosz, Dry, Sarah M, Eilber, Fritz C, Han, Qinghong, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miyake, Kentaro, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Tan, Yuying, Unno, Michiaki   +15 more
core   +2 more sources

Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing

Orphanet Journal of Rare Diseases, 2021
Background Langerhans cell histiocytosis (LCH) is a rare neoplastic disease that occurs in both children and adults, and BRAF V600E is detected in up to 64% of the patients.
Shunqiao Feng, Lin Han, Mei Yue, Dixiao Zhong, Jing Cao, Yibing Guo, Yanling Sun, Hao Zhang, Zhenhua Cao, Xiaodai Cui, Rong Liu   +10 more
doaj   +1 more source

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. [PDF]

, 2017
BackgroundMetastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies.
Ahuja, Amit, Chen, Lei, Daud, Adil, Gill, Japinder, Kamra, Sheily   +4 more
core   +2 more sources

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation

Frontiers in Endocrinology, 2022
BackgroundThe BRAF V600E mutation is the most common genetic variant in papillary thyroid cancer (PTC), but the relationship between the BRAF V600E mutation in PTC and cervical lymph node metastasis (LNM) remains controversial.ObjectiveTo estimate risk ...
Ying Han, Ling Hou, Bowen Zhao, Li Gao, Shiyan Li   +4 more
doaj   +1 more source

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. [PDF]

, 2015
BackgroundPatients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.MethodsTumor tissue from ten patients with advanced BRAF mutation-positive melanoma who ...
Cronin, Maureen T, Falchook, Gerald, Hong, David, Hwu, Patrick, Kim, Kevin B, Kurzrock, Razelle, Stephens, Philip J, Tsimberidou, Apostolia M, Wheler, Jennifer, Yelensky, Roman   +9 more
core   +3 more sources

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. [PDF]

, 2016
Inhibitors of BRAFV600E kinase are currently under investigations in preclinical and clinical studies involving BRAFV600E glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients ...
Berger, Mitchel S, Daynac, Mathieu, Grossauer, Stefan, James, C David, Koeck, Katharina, McMahon, Martin, Meyers, Ian D, Murphy, Nicole E, Nicolaides, Theodore P, Petritsch, Claudia K, Phillips, Joanna J, Truffaux, Nathalene, Truong, Albert Y   +12 more
core   +1 more source

Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.

PLoS ONE, 2013
BackgroundThe aim of this study was to evaluate the proper indication of adjunctive BRAF(V600E) mutation analysis at the time of ultrasound-guided fine-needle aspiration in the diagnosis of thyroid nodules.MethodsThis study included 518 nodules in 479 ...
Jieun Koh, Jong Rak Choi, Kyung Hwa Han, Eun-Kyung Kim, Jung Hyun Yoon, Hee Jung Moon, Jin Young Kwak   +6 more
doaj   +1 more source

Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma

Indian Journal of Endocrinology and Metabolism, 2017
Introduction: Somatic B-type Raf kinase (BRAF) V600E mutation in exon 15 was frequently found in high frequencies associated with papillary thyroid cancer (PTC). The phenotype of these cancers expressed aggressive clinical and pathological features. The
C Gopalakrishnan Nair, Misha Babu, Lalitha Biswas, Pradeep Jacob, Riju Menon, A K Revathy, Krishnanunni Nair   +6 more
doaj   +1 more source

Clinicopathological relevance of BRAF and SMO mutations in Chinese patients with ameloblastoma

All Life, 2023
Ameloblastomas are benign tumors associated with recurrence and morbidity. Mutations in the V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and smoothened (SMO) genes have been identified in ameloblastomas.
Chen Ruixue, Li Hexiang, Hou Yali, Li Xiangjun, Sun Xu, Wang Jie, Zhang Xudong   +6 more
doaj   +1 more source